Drug Profile
Research programme: anticancer therapeutics - Intezyne
Alternative Names: IT-235; NKP-2235; NKP-3752Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Vienna
- Developer Intezyne
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
- Discontinued Haematological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO, Tablet)
- 14 Jan 2015 Discontinued - Preclinical for Haematological disorders in USA (PO)
- 19 Jun 2013 Niiki Pharma has been acquired by Intezyne